ezetimibe has been researched along with Diabetes Mellitus, Type 2 in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (17.31) | 29.6817 |
| 2010's | 64 (61.54) | 24.3611 |
| 2020's | 22 (21.15) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, R; Liu, SY; Zhao, LM | 1 |
| Joung, KH; Kang, SM; Kim, HJ; Kim, JM; Ku, BJ; Lee, JC | 2 |
| Cha, BS; Cho, Y; Choi, JY; Kang, ES; Kim, YE; Lee, BW; Lee, M; Lee, YH; Rhee, H | 1 |
| Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C | 1 |
| Schooling, CM; Yang, G | 1 |
| Li, C; Li, Z; Liang, D; Tu, Y; Zhang, M | 1 |
| Nasir, K; Salami, JA | 1 |
| Ju, SH; Ku, BJ | 1 |
| Chung, KS; Gee, HY; Kim, DY; Park, JY | 1 |
| Bilz, S; Brändle, M; Laimer, M; Lehmann, R; Renström, F; Singeisen, H | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Du, M; Wang, Q; Wang, T; Zhu, S | 1 |
| Bramlage, P; Brandts, J; Brix, JM; Danne, T; Heyer, CHJ; Holl, RW; Müller-Wieland, D; Tittel, SR; Zimny, S | 1 |
| Kim, HS; Kim, NH; Kim, SG; Kim, SS; Ko, SH; Lee, BK; Lee, I; Lee, JH; Moon, JS; Park, IR; Won, KC | 1 |
| Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Elliott-Davey, M; Kosiborod, MN; Liu, Y; Mues, KE; Rosenson, RS; Yazdi, D | 1 |
| Sattar, N; Sillars, A | 1 |
| Ambrosio, G; Armstrong, PW; De Ferrari, GM; Green, JB; Holman, RR; Leonardi, S; Peterson, ED; Stevens, SR; Wamil, M | 1 |
| Abdel-Salam, S; Al-Asaad, H; Aronson, R; Bajaj, HS; Brown, RE; Jiandani, D; Khandwala, H; Steen, O; Venn, K | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Miyazaki, T; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Ibarretxe, D; Masana, L; Plana, N | 1 |
| Amarenco, P; Bruckert, E; Charles, H; Giroud, M; Kim, JS; Labreuche, J; Lavallée, PC; Lee, BC; Mahagne, MH; Meseguer, E; Nighoghossian, N; Steg, PG; Vicaut, É | 1 |
| Andretta, M; Avogaro, A; Degli Esposti, L; Fadini, GP; Morieri, ML; Perrone, V; Plebani, M; Veronesi, C; Vigili de Kreutzenberg, S | 1 |
| Arimura, A; Arimura, H; Deguchi, T; Hashiguchi, H; Kikuti, A; Kurano, M; Nishio, Y; Shinnakasu, A; Yamamoto, K | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Grant, PJ | 1 |
| Cannon, CP; Genest, J; Gupta, M; Mancini, GBJ; Raggi, P; Ray, KK; Santos, RD; Tsigoulis, M; Watts, GF | 1 |
| Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW | 1 |
| Ashidate, K; Hirano, T; Kawamura, M; Kohro, T; Mori, Y; Sakamoto, K; Shiba, T; Tagami, M; Tanaka, A; Watanabe, T; Yamazaki, T | 1 |
| Mikhailidis, DP; Paraskevas, KI | 1 |
| Campos, AM; de Carvalho, LSF; Sposito, AC | 1 |
| Beaubrun, A; Davis, K; Fox, KM; Inomata, H; Kajinami, K; Meyers, J; Nagar, SP; Qian, Y; Rane, PP | 1 |
| Rana, JS; Warraich, HJ | 1 |
| Blazing, M; Bonaca, MP; Braunwald, E; Cannon, C; Giugliano, R; Gutierrez, JA; Park, JG; Tershakovec, A; White, J | 1 |
| Cabrera Mateos, JL; García Díaz, E; Morera Porras, ÓM; Ramírez Medina, D | 1 |
| Brownrigg, J; Catterick, D; Danese, MD; Gleeson, M; Khunti, K; Kondapally Seshasai, SR; Kutikova, L; Ray, KK; Sorio-Vilela, F | 1 |
| Arbel, R; Azuri, J; Hammerman, A | 1 |
| Jin, MM; Li, J; Li, N; Liu, HZ; Miao, XY; Sun, BR; Tian, H; Yan, ST | 1 |
| Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q | 1 |
| Galyavich, AM; Gurevich, VS; Kaminnyi, AI; Kashtalap, VV; Kobalava, JD; Mareev, VY; Shaposhnik, II; Susekov, AV | 1 |
| Brath, H; Kästenbauer, T; Toplak, H; Wascher, TC | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Arao, T; Hajime, M; Inokuchi, N; Kurozumi, A; Matsuoka, H; Mori, H; Narisawa, M; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K; Yamamoto, S | 1 |
| Hirano, T; Iijima, R; Inazawa, T; Kawamura, M; Kitazawa, T; Kohro, T; Mori, Y; Sakamoto, K; Shiba, T; Tagami, M; Tanaka, A; Yamazaki, T | 1 |
| Ciriacks, K; Coly, G; Kidambi, S; Krishnaswami, S; Patel, SB | 1 |
| Federici, M | 1 |
| Chang, E; Choi, JM; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, DI; Park, SE; Park, SW; Rhee, EJ | 1 |
| Irie, Y; Kanamaru, Y; Kaneto, H; Katakami, N; Katsura, T; Kosugi, K; Kubo, F; Nakashoutani, I; Okusu, T; Sakamoto, K; Shimomura, I; Yamamoto, Y; Yoshiuchi, K | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Doi, M; Ito, H; Miyoshi, T; Nakamura, K | 1 |
| Hieshima, K; Jinnouchi, H; Jinnouchi, T; Kajiwara, K; Kurinami, N; Matsui, K; Miyamoto, F; Sugiyama, S; Suzuki, T | 1 |
| Azuma, K; Hanson, ME; Kakikawa, T; Oshima, N; Saito, I; Tershakovec, AM | 1 |
| Chang, E; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Ashidate, K; Chin, R; Hara, H; Hirano, T; Hiyoshi, T; Horiuchi, T; Inazawa, T; Kawamura, M; Kohro, T; Mori, Y; Omura, M; Sakamoto, K; Sekine, N; Shiba, T; Tagami, M; Tanaka, A; Tsujino, M; Watanabe, T; Yamazaki, T | 1 |
| Kobayashi, T; Kurozumi, A; Masuda, D; Mori, H; Okada, Y; Tanaka, Y; Yamashita, S | 1 |
| Ardanaz, E; Arriola, L; Balkau, B; Barroso, I; Boeing, H; Burgess, S; Deloukas, P; Forouhi, NG; Franks, PW; Grioni, S; Kaaks, R; Key, TJ; Langenberg, C; Lotta, LA; Luan, J; McCarthy, MI; Navarro, C; Nilsson, PM; O'Rahilly, S; Overvad, K; Palli, D; Panico, S; Perry, JRB; Quirós, JR; Riboli, E; Rolandsson, O; Sacerdote, C; Salamanca, EC; Sattar, N; Savage, DB; Scott, RA; Sharp, SJ; Slimani, N; Spijkerman, AM; Stewart, ID; Tjonneland, A; Tumino, R; van der A, DL; van der Schouw, YT; Wareham, NJ; Willems, SM | 1 |
| Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG | 1 |
| Collins, PD; Sattar, N | 1 |
| Chien, MN; Ho, HT; Kuo, CP; Lin, AB; Lu, YT; Tsai, IF; Wei, TY; Wu, CL | 1 |
| Duarte, F; Ginsberg, HN; Khavandi, M; Reyes-Soffer, G | 1 |
| Fleg, JL; Galloway, JM; Henderson, JA; Howard, BV; Howard, WJ; Mete, M; Ratner, RE; Roman, MJ; Silverman, A; Stylianou, M; Umans, JG; Weir, MR; Wilson, C | 1 |
| Stein, EA | 1 |
| Böhm, F; Hjemdahl, P; Malmström, RE; Pernow, J; Settergren, M | 1 |
| Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Böhm, F; Kalani, M; Pernow, J; Rydén, L; Settergren, M | 1 |
| Altuntas, Y; Arinc, H; Bolayirli, M; Celebi, H; Dirican, A; Kanat, M; Karagoz, Y; Oguz, A; Sahin, S; Serin, E; Tunckale, A; Yildiz, O | 1 |
| Kanazawa, I; Sugimoto, T; Yamaguchi, T; Yamauchi, M | 1 |
| de Campo, A; März, W; Scharnagl, H; Schmölzer, I; Sourij, H; Stojakovic, T; Wascher, TC | 1 |
| Radermecker, RP; Scheen, AJ | 1 |
| Dunn, FL | 1 |
| Belviso, A; Bossi, AC; Cattaneo, D; Diadei, O; Ene-Iordache, B; Ferrari, S; Iliev, I; Parvanova, A; Remuzzi, G; Rota, S; Ruggenenti, P; Trevisan, R | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 1 |
| Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O | 1 |
| Gensini, GF; Hanson, ME; Le Grazie, C; Rotella, CM; Zaninelli, A | 1 |
| Ishibashi, S; Kotani, K; Miyamoto, M; Nagasaka, S; Okada, K; Osuga, J; Yagyu, H | 1 |
| Katsiki, N; Mikhailidis, DP; Sarigianni, M | 1 |
| Betteridge, DJ; Brudi, P; Farnier, M; Guyton, JR; Johnson-Levonas, AO; Leiter, LA; Lin, J; Shah, A | 1 |
| Choi, JM; Kim, BJ; Kim, L; Kim, SW; Kim, WJ; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ; Sohn, JH; Yang, SJ | 1 |
| Kishimoto, M; Noda, M; Okamoto, M; Osame, K; Sugiyama, T; Takarabe, D | 1 |
| Annuzzi, G; Bozzetto, L; Cipriano, P; Corte, GD; Mangione, A; Patti, L; Riccardi, G; Rivellese, AA | 1 |
| Cariou, B; Costet, P; Le May, C | 1 |
| Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D | 1 |
| Hoffmann, MM; Jacob, S; Konrad, T; Müller-Schewe, T; Winkler, K | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 1 |
| Martin, PY; Saudan, P | 1 |
| Amaha, M; Inoue, H; Kawagoe, Y; Maeda, S; Nakamura, T; Sato, E; Yamagishi, SI | 1 |
| Almquist, T; Farndale, RW; Hjemdahl, P; Jacobson, SH; Lins, PE | 1 |
| Funae, O; Kadonosono, K; Miyamoto, K; Morita, S; Shigematsu, E; Shigematsu, H; Taguri, M; Takatuka, Y; Terauchi, Y; Tokui, M; Yamakawa, T | 1 |
| Ishibashi, S; Miyamoto, M; Nagashima, S; Okada, K; Osuga, J; Takahashi, M; Yagyu, H | 1 |
| Gu, P; Jiang, S; Lu, B; Shao, J; Wang, J; Zhong, Y | 1 |
| Michishita, I; Mizuguchi, I; Nozue, T; Sasaki, M; Tsunoda, T; Yamada, M | 1 |
| Cottrell, DA; Falko, JM; Marshall, BJ | 1 |
| Krone, W; Müller-Wieland, D | 1 |
| Gaudiani, LM; Lewin, A; Meneghini, L; Mitchel, Y; Perevozskaya, I; Plotkin, D; Shah, S | 1 |
| Cimadevilla, C; Guillausseau, PJ; Meas, T; Mouly, S; Timsit, J | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Böhm, F; Pernow, J; Rydén, L; Settergren, M | 1 |
15 review(s) available for ezetimibe and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins | 2023 |
Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Plaque, Atherosclerotic; Proprotein Convertase 9; Subtilisins; Triglycerides; Ultrasonography, Interventional | 2022 |
Management of Lipid Abnormalities in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2019 |
Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Proprotein Convertase 9; Standard of Care | 2020 |
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
Topics: Blood Glucose; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Risk Reduction Behavior; RNA, Small Interfering | 2018 |
A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Treatment Outcome | 2019 |
Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lipoproteins; Liver; Metabolic Syndrome; Treatment Outcome | 2015 |
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Genetic Association Studies; Genetic Variation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Odds Ratio; Polymorphism, Genetic; Proprotein Convertase 9; Receptors, LDL; Risk; Simvastatin | 2016 |
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Meta-Analysis as Topic; Niacin; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Life Style; Lipoproteins; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2017 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Clinical aspects of PCSK9.
Topics: Adolescent; Animals; Azetidines; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fibric Acids; Genes, Dominant; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Mice; Mutation; Nutritional Status; Phenotype; Proprotein Convertase 9; Proprotein Convertases; Protease Inhibitors; Receptors, LDL; Serine Endopeptidases | 2011 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size | 2003 |
[Hyperlipidemia: therapeutic principles in clinical practice].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Insulin Resistance; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Risk Factors; Time Factors; Weight Loss | 2003 |
44 trial(s) available for ezetimibe and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia.
Topics: Adaptor Proteins, Signal Transducing; Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prospective Studies; Rosuvastatin Calcium; Tumor Suppressor Proteins | 2022 |
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study).
Topics: Diabetes Mellitus, Type 2; Elasticity Imaging Techniques; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease | 2022 |
Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol.
Topics: CD8-Positive T-Lymphocytes; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Randomized Controlled Trials as Topic; Rosuvastatin Calcium | 2022 |
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Stu
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Rosuvastatin Calcium | 2023 |
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Reference Values; Sitagliptin Phosphate; Stroke | 2020 |
Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Glycated Hemoglobin; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome | 2020 |
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Monitoring; Ezetimibe; Female; Humans; Male; Plaque, Atherosclerotic; Treatment Outcome; Ultrasonography, Interventional | 2021 |
Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Humans; Male; Prospective Studies | 2017 |
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Vascular Diseases | 2018 |
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Incidence; Israel; Male; Middle Aged; Risk Factors; Secondary Prevention; Survival Rate; Treatment Outcome | 2019 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2013 |
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Sex Factors; Simvastatin | 2013 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Ezetimibe; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pilot Projects; Triglycerides | 2015 |
A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.
Topics: Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypercholesterolemia; Male; Middle Aged; Serum Albumin; Triglycerides | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies | 2015 |
Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.
Topics: Adult; Aged; Atherosclerosis; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Fats; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hyperlipidemias; Male; Middle Aged; Pilot Projects; Postprandial Period; Treatment Outcome | 2016 |
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Tunica Intima; Tunica Media | 2008 |
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; CD40 Ligand; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Platelet Aggregation; Simvastatin; Time Factors; Treatment Outcome | 2009 |
[Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Waist Circumference | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Foot; Forearm; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Simvastatin; Skin; Ultrasonography | 2009 |
A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Drug Administration Schedule; Estradiol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydrocortisone; Luminescent Measurements; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Testosterone; Treatment Outcome | 2009 |
Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Azetidines; Bone and Bones; Cholesterol; Cholesterol, LDL; Collagen Type I; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Osteocalcin; Peptides; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies | 2010 |
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Young Adult | 2010 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Odds Ratio; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Statistics as Topic | 2010 |
Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus.
Topics: Aged; Azetidines; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholestanol; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Phytosterols; Sitosterols | 2010 |
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged | 2011 |
Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Centrifugation, Density Gradient; Cholesterol; Chylomicrons; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Fasting; Female; Humans; Lipoproteins, VLDL; Male; Middle Aged; Placebos; Postprandial Period; Simvastatin; Time Factors; Triglycerides | 2011 |
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles | 2012 |
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Centrifugation, Density Gradient; Diabetes Mellitus, Type 2; Down-Regulation; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2012 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Blood Platelets; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Flow Cytometry; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Leukocytes; Lipids; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Prognosis; Risk Factors; Simvastatin; Young Adult | 2012 |
Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diabetes Mellitus, Type 2; Down-Regulation; Ezetimibe; Female; Humans; Intracellular Signaling Peptides and Proteins; Lipoproteins, HDL; Male; Membrane Glycoproteins; Middle Aged; Niemann-Pick C1 Protein; Phosphatidylcholine-Sterol O-Acyltransferase | 2012 |
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Statistics, Nonparametric; Thiazolidinediones | 2005 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Brachial Artery; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation Mediators; Lipids; Male; Middle Aged; Plethysmography; Regional Blood Flow; Simvastatin; Vasodilation | 2008 |
45 other study(ies) available for ezetimibe and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Ezetimibe; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Meta-Analysis as Topic; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic | 2021 |
Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; ErbB Receptors; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome | 2022 |
Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Ezetimibe; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mendelian Randomization Analysis; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Risk Factors | 2023 |
Therapeutic Inertia in Lipid-Lowering Treatment Intensification: Digital Tools and Performance Management to the Rescue?
Topics: Diabetes Mellitus, Type 2; Ezetimibe; Humans; Lipids | 2022 |
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Glucose; Humans; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiology; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Tertiary Healthcare | 2023 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment.
Topics: Aged; Atorvastatin; Bilirubin; Diabetes Mellitus, Type 2; Ezetimibe; Glucose; Humans; Hypertension | 2023 |
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Austria; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fibric Acids; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Registries | 2023 |
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PCSK9 Inhibitors; Registries; Retrospective Studies; United States | 2020 |
Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes.
Topics: Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Treatment Outcome | 2021 |
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Medication Adherence; Middle Aged; Primary Prevention; Retrospective Studies; Risk Assessment; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prognosis | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
PCSK9 inhibitors- A new age in lipid management?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; PCSK9 Inhibitors; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk; Serine Proteinase Inhibitors | 2017 |
Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
Topics: Aged; Angina, Unstable; Atherosclerosis; Cardiologists; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires | 2017 |
More on carotid atherosclerosis and ezetimibe.
Topics: Atorvastatin; Carotid Artery Diseases; Carotid Stenosis; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans | 2017 |
Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Drug Substitution; Drug Tolerance; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies | 2018 |
Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Smoking; Young Adult | 2019 |
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors | 2018 |
Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Myocardium | 2019 |
[Possibilities of clinical use of ezetimibe Otrio (JSC "AKRIKHIN", Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Risk Factors; Russia | 2019 |
[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Topics: Ambulatory Care; Anticholesteremic Agents; Austria; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Utilization; Ezetimibe; Fibric Acids; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mass Screening; Risk Factors; Treatment Outcome; Triglycerides | 2012 |
Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Body Mass Index; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Prospective Studies; Simvastatin; Waist Circumference | 2015 |
Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Topics: Animals; Azetidines; Blood Glucose; Blotting, Western; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ezetimibe; Glucagon-Like Peptide 1; Insulin; Intestinal Mucosa; L Cells; Male; MAP Kinase Signaling System; Mice; Rats; Rats, Sprague-Dawley; Specific Pathogen-Free Organisms | 2015 |
The usefulness of a cholesterol absorption inhibitor in Japanese type 2 diabetes patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Biomarkers; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Japan; Lipids; Male; Middle Aged | 2015 |
Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Serine Endopeptidases | 2015 |
Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
Topics: Animals; Anticholesteremic Agents; Autophagy; Biomarkers; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Fatty Liver; Gene Expression Regulation; Hepatocytes; Lipids; Liver; Macrolides; Male; Obesity; Palmitic Acid; Rats, Inbred OLETF; RNA, Messenger | 2015 |
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Back Pain; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Influenza, Human; Middle Aged; Myocardial Infarction; Nasopharyngitis; Pruritus; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Stroke; Urinary Tract Infections | 2016 |
Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes.
Topics: Adenosine Triphosphate; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Colony Count, Microbial; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Latent Tuberculosis; Leukocytes; Lipid Metabolism; Macrophages; Mycobacterium tuberculosis; Transcriptome; Triglycerides; Tuberculosis, Pulmonary | 2017 |
Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Tunica Intima; Tunica Media | 2008 |
[Ezetimibe (Ezetrol) in patients with diabetes].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Intestinal Absorption | 2009 |
Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients.
Topics: Ankle; Anticholesteremic Agents; Arteries; Azetidines; Blood Flow Velocity; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Triglycerides | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides | 2010 |
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial: comment on Ruggenenti et al.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2010 |
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Young Adult | 2011 |
Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ezetimibe; Glucagon-Like Peptide 1; Hyperglycemia; Insulin-Secreting Cells; Male; Rats; Rats, Inbred Strains | 2011 |
[Nephrology].
Topics: Anticholesteremic Agents; Azathioprine; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Lupus Nephritis; Mycophenolic Acid; Nephrology; Renal Dialysis; Secondary Prevention; Simvastatin; Treatment Outcome | 2012 |
Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.
Topics: Albumins; Albuminuria; Azetidines; Blood Pressure; Body Mass Index; Chemokine CCL2; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Triglycerides | 2012 |
Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes.
Topics: Aged; Azetidines; Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Sex Factors; Triglycerides | 2012 |
Effect of ezetimibe on insulin secretion in db/db diabetic mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Diabetes Complications; Diabetes Mellitus, Type 2; Ezetimibe; Glucose Intolerance; Hypercholesterolemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Kinetics; Male; Mice; Mice, Congenic; Mice, Mutant Strains; Random Allocation; Specific Pathogen-Free Organisms | 2012 |
Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Azetidines; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Homeostasis; Humans; Japan; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Treatment Outcome; Weight Loss | 2013 |
[Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Risk Factors; Simvastatin; Triglycerides | 2005 |
Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Creatinine; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fenofibrate; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged | 2006 |